Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Serially Testing Brain Tumor Samples Reveals Treatment Response in Glioblastoma Patients

By LabMedica International staff writers
Posted on 16 Oct 2025

Glioblastoma (GBM) is the most aggressive form of brain cancer, known for rapid growth, recurrence, and resistance to treatment. More...

Understanding how tumors respond to therapy remains challenging since imaging often fails to distinguish true progression from immune-related inflammation. Now, a new study shows that repeatedly sampling brain tumor tissue during treatment can uncover immune responses and microenvironmental changes that conventional scans may miss.

The research, led by Mass General Brigham (Boston, MA, USA) through the multi-institutional Accelerating GBM Therapies Through Serial Biopsies TeamLab, involved more than 100 scientists and clinicians across the United States. Conducted with funding from Break Through Cancer, the study tested an oncolytic virus immunotherapy called CAN-3110, designed to selectively infect and kill tumor cells while stimulating the immune system. Researchers collected 96 tumor samples over four months from two patients with recurrent GBM enrolled in the clinical trial.

The findings, published in Science Translational Medicine, revealed that repeated tumor biopsies captured significant immune activation and biochemical shifts within the tumor environment, even when MRI scans suggested disease worsening. This phenomenon, known as pseudoprogression, occurs when immune activity causes inflammation that mimics tumor growth on imaging. Of the two patients treated, one showed a positive immune response while the other maintained stable disease, confirming the potential of longitudinal tissue analysis to detect subtle therapeutic effects.

Using multi-omic analysis, the team integrated genetic, proteomic, metabolic, and AI-enabled pathology data to map tumor evolution over time. The results highlight the value of incorporating serial biopsies into clinical trials to provide real-time insight into treatment efficacy and immune response. The researchers are now expanding the platform to 12 patients and adapting it for additional vaccine-based immunotherapies, aiming to redefine GBM trial design and improve future drug development.

“Standard practice is to not serially sample a patient’s brain tumor as they undergo treatment but instead to take a sample only once before a treatment and then follow a patient’s response using MRI,” said E. Antonio Chiocca, lead investigator of the study. “But this study’s findings suggest that this thinking and practice may need to change to revolutionize how patients can monitor their disease.”

Related Links:
Mass General Brigham


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.